Biotech News
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
ir.allogene.com2026-05-06 14:55 EST
Pivotal, Randomized Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Positions Company at the Forefront of MRD-Guided 1L Consolidation Treatment in Both Academic and Community Cancer Centers, and Advances a Broader